Abstract
New methods based on reactive organometallic precursors containing organic functional groups that are generally responsible for physiologic responses are being exploited for preparation of radiopharmaceutials. This program focuses on the design of new chemistry (molecular architecture) and technology as opposed to the application of known reactions to the synthesis of specific radiopharmaceutical. The new technology which is often based on organoborane chemistry is then utilized in nuclear medicine research at the UT Biomedical Imaging Center and in collaboration with colleagues at other DOE. facilities such as Brookhaven National Laboratory and Oak Ridge National Laboratory. New radiopharmaceutical are evaluated preclinically by colleagues at UT, Emory University and The University of Pennsylvania, and by Nova Screen.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
